Erasca develops oncology drugs intended to provide precision oncology options. The company's drugs are being developed through multiple discovery programs for undisclosed targets that are biological drivers of cancer and are pursuing additional opportunities for pipeline expansion through academic and biopharmaceutical collaborations, providing patients with new potential solutions to not just treat but cure cancer. Erasca was founded in 2018 and is headquartered in San Diego, California.

Erasca's core mission is centered around eradicating cancer by revolutionizing the way it is detected, treated, and ultimately prevented. With a strong commitment to scientific innovation and collaboration, Erasca seeks to develop groundbreaking therapies and technologies that have the potential to transform the lives of cancer patients worldwide. By fostering a culture of excellence and dedication, Erasca aims to make a lasting impact in the fight against cancer and create a future where this devastating disease is a thing of the past.

• Patient-first: Erasca is dedicated to putting patients at the center of everything they do, prioritizing their needs and well-being above all else.
• Collaboration: Erasca values teamwork and collaboration, fostering an environment where diverse perspectives are welcomed and encouraged to drive innovation.
• Integrity: Erasca operates with the highest ethical standards, maintaining transparency and honesty in all aspects of their business.
• Agility: Erasca is adaptable and responsive to change, embracing new ideas and technologies to stay ahead of the curve in the fight against cancer.